At this time, the OASIS 1 study showed that oral SMG 50 mg had a safety profile consistent with those previously reported for subcutaneous SMG in obesity and with other drugs in the GLP-1 receptor agonist class. This evidence concerns the gene GLP1R and obesity disorder.